Assessing the Risk of Birth Defects Associated with Exposure to Fixed-Dose Combined Antituberculous Agents during Pregnancy in Rats

Table 4

Hematological Profile of Rats at first filial.

Groups	SOE	NOF	WBC (Mean ± SEM)	RBC (Mean ± SEM)	HGB (Mean ± SEM)	HCT (Mean ± SEM)	PCT (Mean ± SEM)	LYPM (Mean ± SEM)	NEU (Mean ± SEM)
Group 1	ORG	6	5.433±0.2319	6.677±0.1444	13.70±0.2646	40.92±0.6519	792.5±18.92	3.705±0.2207	1.345±0.1276
Group 2	ORG	6	4.983±1.101	6.330±0.2752	11.97±0.7864	38.83±1.456	372.7±72.42^∗	3.722±0.8835	0.8100±0.1643^∗
Group 3	ORG	6	6.517±0.7510	6.108±0.3862	11.98±0.695	37.17±1.615	475.7±100.7^∗	4.717±0.4642	1.622±0.2774

SOE: stage of exposure, NOF: number of animals, ORG: organogenesis, WBC: white blood cell count, RBC: red blood cell count, HGB: hemoglobin count, HCT: haematocrit, PCT: platelet count, LYPM: lymphocyte, NEU: neutrophiles.
^∗𝑃≤0.05 compared with group 1 (control).
Group 1: control group. Group 2: administered with clinical dose (51.4 mg/kg/day) of fixed-dose combined antituberculous agents. Group 3: administered with clinical dose of fixed-dose combined antituberculous agents plus 10 mg/kg/day of Vitamin C.